Drug Profile
Vemircopan - Alexion AstraZeneca Rare Disease
Alternative Names: ACH 5228; ACH-0145228; ALXN 2050Latest Information Update: 04 Dec 2023
Price :
$50
*
At a glance
- Originator Achillion Pharmaceuticals
- Developer Achillion Pharmaceuticals; Alexion AstraZeneca Rare Disease
- Class Amides; Azabicyclo compounds; Halogenated hydrocarbons; Immunotherapies; Indazoles; Pyrimidines; Small molecules; Urologics
- Mechanism of Action Complement factor D inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II IgA nephropathy; Lupus nephritis; Myasthenia gravis
- Phase I Autoimmune disorders
- Discontinued Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 04 Dec 2023 Discontinued - Phase-I for Paroxysmal nocturnal haemoglobinuria (In volunteers) in USA (PO), prior to December 2023 (AstraZeneca pipeline, December 2023)
- 04 Dec 2023 Discontinued - Phase-II for Paroxysmal nocturnal haemoglobinuria in United Kingdom, Turkey, Spain, South Korea, Italy, Canada, New Zealand (PO), prior to December 2023 (AstraZeneca pipeline, December 2023)
- 10 Oct 2023 Alexion plans a phase I trial for Healthy volunteers (PO) (NCT06071442)